Literature DB >> 31967004

CYSTIC PROLACTINOMA: A SURGICAL DISEASE?

Kayur R Bhavsar, Kristi D Silver.   

Abstract

OBJECTIVE: Since the advent of dopamine agonists, prolactinomas have been primarily treated medically. However, studies show conflicting data on whether these agents are as effective as surgery for predominantly cystic prolactinomas. We present a case of a patient with a cystic prolactinoma for which surgery was selected as first-line therapy.
METHODS: Literature review.
RESULTS: A 26-year-old African American man presented to an outside hospital with complaints of dull right-sided headaches for 1 week. The headache worsened over the next few days, which prompted him to go to the emergency room. The evaluation included a head computed tomography, which demonstrated a 4-cm solid/cystic pituitary mass with possible hemorrhagic conversion and compression of the optic chiasm. He was transferred to University of Maryland Medical Center for neurosurgical evaluation. He denied symptoms of pituitary hormone excess or deficiency. He denied visual symptoms, though formal visual field testing demonstrated temporal hemianopia. Hormonal evaluation revealed hyperprolactinemia (prolactin, 1,627 ng/mL) and central hypothyroidism (thyroid-stimulating hormone, 2.72 μIU/mL; free thyroxine, 0.5 ng/dL). Because of the large cystic component of the prolactinoma and clinical evidence for compression of the optic chiasm, the patient underwent transsphenoidal resection of the mass. Postoperatively, the patient was started on bromocriptine for suppression of residual prolactinoma tissue. Notably, the patient developed several complications postoperatively, including diabetes insipidus and secondary hypogonadism.
CONCLUSION: Initial management strategies for cystic prolactinomas have been debated. This case highlights the importance of careful consideration of both medical and surgical treatment options in patients with prolactinomas with large cystic components.
Copyright © 2019 AACE.

Entities:  

Year:  2019        PMID: 31967004      PMCID: PMC6876970          DOI: 10.4158/ACCR-2018-0267

Source DB:  PubMed          Journal:  AACE Clin Case Rep        ISSN: 2376-0605


  7 in total

1.  Surgery for prolactinomas.

Authors:  Ashfaq A Razzaq; Rashid Jooma; Shahid Ahmed
Journal:  J Pak Med Assoc       Date:  2006-04       Impact factor: 0.781

2.  Hyperprolactinaemia associated with a complex cystic pituitary mass: medical versus surgical therapy.

Authors:  W J Inder; M R Macfarlane
Journal:  Intern Med J       Date:  2004 Sep-Oct       Impact factor: 2.048

Review 3.  Macroprolactinoma: a diagnostic and therapeutic update.

Authors:  P Iglesias; J J Díez
Journal:  QJM       Date:  2013-01-16

4.  Significance of surgical management for cystic prolactinoma.

Authors:  Toshihiro Ogiwara; Tetsuyoshi Horiuchi; Alhusain Nagm; Tetsuya Goto; Kazuhiro Hongo
Journal:  Pituitary       Date:  2017-04       Impact factor: 4.107

5.  Dopamine Agonists Can Reduce Cystic Prolactinomas.

Authors:  Alexander Faje; Paweena Chunharojrith; Joshipura Nency; Beverly M K Biller; Brooke Swearingen; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

6.  Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.

Authors:  J Kreutzer; R Buslei; H Wallaschofski; B Hofmann; C Nimsky; R Fahlbusch; M Buchfelder
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

7.  Non-surgical management of cystic prolactinomas.

Authors:  Biji Bahuleyan; Girish Menon; Suresh Nair; B R M Rao; H V Easwer; Kumar Krishna
Journal:  J Clin Neurosci       Date:  2009-08-20       Impact factor: 1.961

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.